Last reviewed · How we verify
NCT07047976: ASD
Mechanism Study of Sulforaphane in ASD Improvement
NA trial testing Sulforaphane in Autism Spectrum Disorder. Withdrawn.
1 July 2025
Quick facts
| Lead sponsor | Jian-Jun Ou |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 September 2024 |
| Primary completion | 1 July 2025 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sulforaphane — full drug profile →
Conditions studied
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
- Sulforaphane — all drugs for Sulforaphane →
Sponsor
Jian-Jun Ou — full company profile →
Who can join
Adults 12 to 34, any sex, with Autism Spectrum Disorder or Sulforaphane. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to find out if sulforaphane (SFN) can improve social skills and behavior in people with Autism Spectrum Disorder (ASD). ASD is a developmental disorder that affects how children and teenagers interact with others. The number of people diagnosed with ASD has been rising, putting a lot of pressure on families and society. The investigators hope this study will lead to new treatments. The main questions the investigators want to answer are: Can sulforaphane help improve social communication in people with ASD? How does sulforaphane affect the balance of certain chemicals in the brain? The investigators will recruit 50 participants aged 12 to 34 diagnosed with ASD and 30 healthy volunteers for comparison. Participants will: Take 3 capsules of sulforaphane each day for 8 weeks. Complete regular psychological tests, undergo brain scans, and have their brain activity monitored to assess the treatment's effectiveness. Through this study, the investigators aim to discover the potential benefits of sulforaphane for individuals with ASD and provide new insights for future treatment options.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07047976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sulforaphane
Trials testing the same drug.
- NCT06594536 — Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperacti · NA · not yet recruiting
- NCT05653492 — Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease · Phase 2 · active not recruiting
- NCT04848792 — Treatment Strategy to Enhance Nrf2 Signaling in Older Adults · NA · completed
- NCT04805957 — Validation Digital Bio-markers During Sulforaphane Treatment. · NA · enrolling by invitation
- NCT05408559 — Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES · Phase 1, PHASE2 · recruiting
Other recruiting trials for Autism Spectrum Disorder
Currently open trials in the same condition.
- NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
- NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting
Other Jian-Jun Ou trials
Trials by the same sponsor.
- NCT07282366 — Video Intervention to Reduce Depression-related Stigma Among Adolescents · NA · not yet recruiting
- NCT07110181 — Blended Unified Protocol for Chinese Adolescents With Non-Suicidal Self-Injury: A Randomized Controlled Trial · NA · not yet recruiting
- NCT06858540 — Blended Unified Protocol in Chinese Adolescents With Non-Suicidal Self-Injury · NA · recruiting
- NCT06305988 — Neuroregulatory Effect and Mechanism of tDCS on Medial Prefrontal Cortex in ASD · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07047976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jian-Jun Ou
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07047976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing